Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

Table 2 The effect of virus arming on the survival of patients with different FcgR genotype combinations

Genotype		Treated with GM-CSF virus			Treated with CD40L virus			Treated with GM-CSF and CD40L viruses			Treated with unarmed virus
	N (all patients)	N	P	+ or -	N	P	+ or -	N	P	+ or -	N	P	+ or -
FFHH	24	17	0,783	+/−	4	0,047	+	2	0,034	+	4	0,067	-
FFHR	61	42	0,004	+	9	0,106	+	4	0,222	+	13	<0,0005	-
FFRR	39	27	0,006	+	6	0,175	+/−	2	0,166	+	8	0,016	-
VFHH	30	22	0,194	+	6	0,182	+	5	0,103	+	7	0,283	-
VFHR	39	28	0,093	+	10	0,331	+	4	0,025	+	5	0,179	-
VFRR	22	17	0,061	+	2	NA		0	NA		3	0,122	-
VVHH	7	7	NA		0	NA		0	NA		0	NA
VVHR	10	8	0,081	+	0	NA		0	NA		2	0,081	-
VVRR	1	1	NA		0	NA		0	NA		0	NA

P = log rank, + or = benefits or disadvantageous (= better or worse OS estimate) when compared to others.
Kaplan-Meier analyses were performed to study the effect of the virus arming (GM-CSF, CD40L, both or unarmed) on survival of patient with different genotype combinations. Calculations were made by first restricting the study population by each genotype combination and then comparing the overall survival of patient treated with a certain type of virus versus all others. Abbreviations: H histidine allele of FcgRIIa, V valine allele of FcgRIIIa, F phenylalanine allele of FcgRIIIa, CD40L, CD40 ligand, GM-CSF granulocyte macrophage colony-stimulating factor.

ISSN: 1479-5876